YARWOOD LIMITED

Financial Health Assessment: YARWOOD LIMITED

1. Financial Health Score: F Explanation: The company is in critical condition, displaying severe symptoms of financial distress. As of February 2026, the business has negative net assets (£-111,135) and an accumulated deficit of over £1.1 million. While it remains technically solvent due to the implied support of its group creditors, on a standalone basis, its financial immune system is entirely compromised, and its liquidity is virtually non-existent.

2. Key Vital Signs

• Net Assets (Blood Pressure): Critical Low (-£111,135) Just a year ago, the company had a healthy positive equity of £1.24 million. The sudden swing to negative net assets indicates a massive internal hemorrhage of value, destroying the company's financial foundation.
• Liquidity / Working Capital (Heart Rate): Flatline (£2 current assets vs £139,470 current liabilities) With virtually no cash or debtors remaining to cover short-term debts, the company has zero ability to meet its financial obligations independently. The pulse of daily operations has stopped without external life support.
• Retained Earnings/P&L Reserve (Organ Health): Severe Trauma (-£1,133,803) The P&L reserve plummeted from a positive £219,320 to a deficit of over £1.1 million in a single year. This represents a catastrophic loss that has wiped out all historical retained profits and the entire share capital/premium reserve.
• Intercompany Balances (Circulatory System): Complete Disruption The £1.2 million owed to this company by its group has vanished, replaced by a new £139,470 debt owed by this company to the group. The financial blood flow has completely reversed.

3. Diagnosis

Severe Group-Dependent Insolvency following Major Structural Hemorrhage

The patient has suffered an acute financial shock between March 2025 and February 2026. The dramatic shift in the balance sheet is not the result of normal trading losses (as no revenue or cost of sales is reported in these small-company accounts), but rather a structural rearrangement of group finances.

Specifically, the company wrote off or forgave a £1.2 million intercompany loan that was previously its primary asset. Simultaneously, it took on a new £139,470 creditor owed to group undertakings. This surgical removal of the asset was fatal to the company's standalone balance sheet, pushing it into negative equity.

Yarwood Limited is currently functioning as a shell, kept alive entirely on the life support of its parent/group network. If the group undertakings were to call in their £139,470 debt, the company would face immediate, terminal insolvency. Its SIC code (Wholesale of hides, skins and leather) suggests a trading origin, but the current balance sheet indicates it holds no stock, no cash, and no trade debtors—only a £28,335 stake in a subsidiary and a large deficit.

4. Recommendations

• Secure Group Life Support (Formal Waiver): Given that the company cannot repay the £139,470 intercompany creditor, the group parent must provide a formal, legally binding written assurance (a waiver of repayment) that this debt will not be called in for at least 12 months beyond the balance sheet date. Without this, the going concern status is untenable.
• Capital Transfusion (Re-capitalisation): If the group intends to keep Yarwood Limited active, it needs an immediate capital injection. This should be done either by injecting new equity share capital or by converting the £139,470 intercompany debt into share capital, thereby restoring positive net assets and stabilizing the patient.
• Consider Palliative Care (Voluntary Strike-Off): If Yarwood Limited no longer serves a strategic purpose—since it holds only a dormant subsidiary investment and carries out no apparent trading activity—the group should consider winding the company up. Applying for voluntary strike-off would prevent further administrative costs and allow the subsidiary investment to be transferred elsewhere before dissolution.